amobarbital 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| hypnotics, barbituric acid derivatives | 184 | 57-43-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
| 0.10 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 95 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05CA02 | NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Barbiturates, plain |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D018682 | GABA Agents |
| MeSH PA | D018757 | GABA Modulators |
| MeSH PA | D006993 | Hypnotics and Sedatives |
| MeSH PA | D018377 | Neurotransmitter Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| General anesthesia | indication | 50697003 | |
| Severe anxiety (panic) | indication | 80583007 | |
| Epilepsy | indication | 84757009 | DOID:1826 |
| Seizure disorder | indication | 128613002 | |
| Insomnia | indication | 193462001 | |
| Status epilepticus | indication | 230456007 | DOID:1824 |
| Narcoanalysis | indication | 302683009 | |
| Local anesthesia | indication | 386761002 | |
| Apnea | contraindication | 1023001 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Alcoholism | contraindication | 7200002 | |
| Hyperammonemia | contraindication | 9360008 | |
| Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
| Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
| Disorder of lung | contraindication | 19829001 | DOID:850 |
| Depressive disorder | contraindication | 35489007 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Hyperactive behavior | contraindication | 44548000 | |
| Low blood pressure | contraindication | 45007003 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Hepatic failure | contraindication | 59927004 | |
| Substance abuse | contraindication | 66214007 | |
| Hepatic coma | contraindication | 72836002 | DOID:12550 |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Decreased respiratory function | contraindication | 80954004 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Pneumonia | contraindication | 233604007 | DOID:552 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Sleep automatism | contraindication | 247962006 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Respiratory insufficiency | contraindication | 409623005 | |
| Porphyria | contraindication | 418470004 | |
| Acute exacerbation of asthma | contraindication | 708038006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.82 | acidic |
| pKa2 | 9.51 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4017495 | VUID |
| N0000178972 | NUI |
| D00555 | KEGG_DRUG |
| 64-43-7 | SECONDARY_CAS_RN |
| 1314242 | RXNORM |
| C0002640 | UMLSCUI |
| CHEBI:2673 | CHEBI |
| CHEMBL267894 | ChEMBL_ID |
| DB01351 | DRUGBANK_ID |
| CHEMBL2105941 | ChEMBL_ID |
| D000654 | MESH_DESCRIPTOR_UI |
| 2164 | PUBCHEM_CID |
| 1111 | INN_ID |
| GWH6IJ239E | UNII |
| 4185 | MMSL |
| 72389 | MMSL |
| d00171 | MMSL |
| 372831009 | SNOMEDCT_US |
| 387343004 | SNOMEDCT_US |
| 73756003 | SNOMEDCT_US |
| 4017494 | VANDF |
| 4017495 | VANDF |
| 001408 | NDDF |
| 001409 | NDDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Amytal Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-4303 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.50 g | INTRAMUSCULAR | Unapproved drug other | 25 sections |
| Amytal Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-4303 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.50 g | INTRAMUSCULAR | Unapproved drug other | 25 sections |